Maternal Medication Exposure Records: Clinical Implications, Epidemiology, and Best Practice Recommendations

Abstract

Maternal medication exposure records provide critical data for assessing the safety of drug therapies during pregnancy. These records are essential for optimizing maternal and fetal outcomes, as medication use in pregnancy is common and presents unique pharmacological challenges. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical assessment, and management of medication exposure during gestation. It highlights recent advances in pharmacovigilance, emerging therapies, and guideline-driven strategies to ensure evidence-based care for pregnant patients, underscoring the importance of accurate documentation and multidisciplinary collaboration in clinical practice.

Introduction

Medication use during pregnancy is a complex clinical issue involving the balancing of maternal health needs with fetal safety. The physiological changes of pregnancy alter drug pharmacokinetics and pharmacodynamics, necessitating careful assessment and monitoring. Maternal medication exposure records serve as an indispensable tool for clinicians, researchers, and regulatory bodies, providing a foundation for evidence-based decision-making and pharmacovigilance. Comprehensive records facilitate the identification of drug safety signals, elucidate associations with adverse pregnancy outcomes, and inform guideline development. This article reviews the epidemiology, mechanisms, risk factors, clinical features, diagnostic approaches, and therapeutic strategies associated with maternal medication exposure, incorporating recent research and current standards of care.

Epidemiology / Disease Burden

The prevalence of medication use during pregnancy is significant, with estimates indicating that over 90% of women are exposed to at least one prescription or over-the-counter medication during gestation. This includes chronic therapies for pre-existing conditions, acute treatments, and inadvertent exposures. Polypharmacy is increasingly common due to advanced maternal age, comorbidities, and expanded therapeutic options. Epidemiological data from teratology information services and pregnancy exposure registries reveal that certain drug classes—such as antihypertensives, antidepressants, and antibiotics—are frequently used. However, only a fraction of medications are supported by robust safety data in pregnancy, leading to knowledge gaps and potential clinical uncertainty. The burden of medication-related adverse pregnancy outcomes—including congenital anomalies, preterm birth, and fetal growth restriction—remains a public health concern, underscoring the need for meticulous exposure documentation and research.

Pathophysiology

Pregnancy induces profound physiological changes affecting drug absorption, distribution, metabolism, and excretion. Increased plasma volume and altered protein binding can lower drug concentrations, whereas changes in hepatic enzyme activity may enhance or reduce metabolism depending on the substrate. Placental transfer mechanisms, including passive diffusion and active transport, determine fetal exposure. The timing of exposure in relation to gestational age is critical; teratogenic risk is highest during organogenesis (weeks 3–8), while later exposures may impact fetal growth or neurodevelopment. The pathophysiological consequences of medication exposure are drug-specific, ranging from structural malformations (e.g., valproate-induced neural tube defects) to functional disturbances (e.g., SSRIs and neonatal adaptation syndrome). Understanding these mechanisms is essential for risk stratification and counseling.

Risk Factors

Several maternal, fetal, and drug-related factors modulate the risk associated with in utero medication exposure. Maternal comorbidities (such as epilepsy, diabetes, hypertension), genetic polymorphisms affecting drug metabolism, and nutritional status influence susceptibility. Concomitant use of multiple medications increases the risk of drug interactions and cumulative toxicity. The teratogenic potential is also determined by drug class, dose, frequency, and duration of exposure. Socioeconomic factors, healthcare access, and health literacy contribute to inappropriate medication use, underreporting, and inadequate follow-up. Unintended pregnancies may result in inadvertent first-trimester exposures before pregnancy recognition, further complicating risk assessment.

Clinical Features

The clinical manifestations of adverse drug effects in pregnancy are highly variable. Some exposures may be asymptomatic initially but manifest as congenital anomalies, neurodevelopmental disorders, or growth abnormalities detected postnatally. Others, such as NSAID-induced oligohydramnios or ACE inhibitor fetopathy, can present with acute complications in utero. Maternal adverse events may include exacerbation of chronic conditions or drug-induced organ dysfunction. A high index of suspicion, detailed exposure histories, and multidisciplinary evaluation are critical for timely recognition and intervention.

Diagnosis

Diagnosing medication-related adverse outcomes in pregnancy requires a systematic approach. Detailed maternal medication exposure records—including drug name, dose, route, frequency, timing, and indication—are fundamental. Correlation with gestational age at exposure, maternal health status, and family history is essential. Prenatal diagnostic tools, such as targeted ultrasonography and molecular testing, aid in detecting structural anomalies. Postnatal evaluation may involve physical examination, neurodevelopmental assessment, and laboratory investigations. Integration of data from pregnancy registries and pharmacovigilance systems enhances case ascertainment and causal inference. Prompt reporting to teratology information services is recommended for ongoing surveillance and research.

Treatment & Management

Management strategies focus on optimizing maternal health while minimizing fetal risk. Alternative therapies with established safety profiles should be considered where possible. In cases where essential medications are required (e.g., antiepileptics, insulin, antihypertensives), individualized risk-benefit analysis and dose adjustment are paramount. Preconception counseling and medication review are advised for women with chronic conditions. Ongoing fetal monitoring—including serial ultrasonography and maternal-fetal medicine consultations—may be warranted for high-risk exposures. Postpartum follow-up should include assessment of neonatal adaptation and developmental milestones. Clinicians should engage in shared decision-making, provide evidence-based counseling, and document discussions thoroughly in the maternal record.

Recent Advances / Emerging Therapies

Recent advances in pharmacogenomics and precision medicine hold promise for improving risk stratification and therapeutic decision-making in pregnant patients. Large-scale pregnancy exposure registries and real-world data analytics enhance the detection of rare adverse outcomes and facilitate post-marketing surveillance. Novel drug formulations, including extended-release and targeted delivery systems, may reduce fetal exposure while maintaining maternal efficacy. Digital health innovations, such as electronic maternal medication exposure records and clinical decision support tools, streamline documentation and enable rapid access to safety information. Ongoing research into placental drug transporters, biomarkers of teratogenicity, and epigenetic effects is expanding the knowledge base and informing emerging therapeutic strategies.

Guideline Recommendations

Multiple professional organizations provide guidance on medication use in pregnancy, emphasizing individualized risk assessment and documentation. The American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the U.S. Food and Drug Administration (FDA) advocate for comprehensive exposure records, evidence-based prescribing, and patient counseling. The FDA's Pregnancy and Lactation Labeling Rule (PLLR) mandates clear labeling of drug risks and encourages reporting of adverse outcomes. Guidelines recommend consultation with teratology information services for complex cases and multidisciplinary collaboration involving obstetricians, pharmacists, and pediatricians. Implementation of standardized documentation templates and integration with electronic health records (EHRs) are promoted to improve data quality and facilitate research.

Conclusion

Maternal medication exposure records are integral to the provision of safe, evidence-based care in pregnancy. Accurate and comprehensive documentation supports clinical decision-making, enhances pharmacovigilance, and advances the understanding of medication effects on maternal and fetal health. Ongoing research, guideline development, and digital innovation are essential to address knowledge gaps and optimize outcomes. Clinicians must remain vigilant, utilize multidisciplinary resources, and engage patients in informed discussions to ensure the best possible care for mothers and their children.